Determining whether a vaccine can protect against severe disease and death from COVID-19 may not be possible in phase 3 clinical trials and will often require long-term, ongoing studies after widespread deployment of a vaccine.

To ensure ongoing evaluation of vaccine safety, well-supported pharmacovigilance studies after licensure will be necessary.